Trump Calls Medical Cannabis the 'Best Alternative' After Rescheduling

A Presidential Endorsement That Changes the Conversation

In the hours following the Department of Justice's historic decision to reclassify state-licensed medical marijuana from Schedule I to Schedule III, President Donald Trump made a statement that many in the cannabis industry never expected to hear from the Oval Office. He called medical cannabis "the best of all the alternatives" for people suffering from serious illnesses — a personal endorsement that goes well beyond the bureaucratic language of rescheduling orders.

The comment, made on April 24, 2026, marked the first time a sitting U.S. president has spoken so favorably about cannabis in a public setting. While Trump's executive order directing the DOJ to pursue rescheduling was issued months earlier, the personal praise adds a cultural stamp of approval that policy documents alone cannot provide.

What the DOJ Actually Did

Acting Attorney General Todd Blanche signed a two-phase order on April 23, 2026. Phase one immediately reclassifies state-licensed medical marijuana from Schedule I — the same category as heroin and LSD — to Schedule III, alongside drugs like ketamine and Tylenol with codeine. Phase two establishes an expedited hearing process to evaluate broader rescheduling for all cannabis, with proceedings scheduled to begin June 29 and conclude no later than July 15, 2026.

The immediate impact is significant. Medical marijuana operators licensed under state programs will no longer face the punishing tax burden of IRS Code Section 280E, which has prevented cannabis businesses from deducting ordinary business expenses. Under Schedule III classification, these businesses can claim the same deductions as any other legal enterprise — a change that could save the industry hundreds of millions of dollars annually.

Why Trump's Words Matter Beyond Policy

Policy analysts are quick to note that Trump's personal endorsement carries weight that extends far beyond the legal technicalities. When a president describes cannabis as the best option for sick patients, it sends signals to multiple audiences simultaneously.

For the medical community, it provides political cover for physicians who have been reluctant to discuss cannabis with patients due to its Schedule I status. The American Medical Association has long called for reclassification to facilitate research, and Trump's comments align with that position.

For the financial sector, presidential approval reduces the political risk associated with cannabis lending. Banks and credit unions that have avoided cannabis accounts due to federal enforcement concerns now have the clearest signal yet that the White House views medical cannabis favorably.

For international markets, Trump's endorsement may influence cannabis policy discussions in countries that look to American drug scheduling as a benchmark. Nations considering their own medical cannabis frameworks can point to the U.S. reclassification as precedent.

The Research Angle

One of the most consequential changes is the removal of research barriers. Under Schedule I, scientists needed special DEA licenses to study cannabis — a process that could take years and limited research to a single federally approved grow facility at the University of Mississippi.

Under Schedule III, medical marijuana researchers will no longer need to navigate the onerous Schedule I licensing process. This opens the door for universities, hospitals, and pharmaceutical companies to conduct the rigorous clinical trials that have been nearly impossible to perform in the United States.

The timing is notable. Over 70 cannabis-related studies have already been published in 2026 alone, covering everything from cancer therapy to chronic pain management. With research barriers falling, that pace is expected to accelerate dramatically.

What This Does Not Do

Despite the significance of Trump's comments and the DOJ's action, important limitations remain. The rescheduling does not legalize marijuana for recreational use under federal law. It does not resolve the banking crisis entirely — the SAFE Banking Act remains stalled in Congress. And it applies specifically to state-licensed medical operations, leaving recreational markets in a legal gray area.

The hearing beginning June 29 will examine whether to extend Schedule III classification to all cannabis, including recreational programs. If that broader rescheduling occurs, it would affect the entire $47 billion U.S. cannabis market.

Industry Reaction

Cannabis industry stakeholders responded with cautious optimism. Major multi-state operators saw immediate stock price gains, with the AdvisorShares Pure US Cannabis ETF (MSOS) jumping significantly in after-hours trading. Companies like Curaleaf and Green Thumb Industries issued statements welcoming the move while noting that more comprehensive reform is still needed.

Small operators expressed mixed feelings. While the 280E tax relief is welcome, many pointed out that the largest benefits flow to companies with established medical licenses. Operators in recreational-only markets must wait for the Phase Two hearing to see meaningful change.

The Political Calculus

Trump's embrace of medical cannabis reflects broader political realities. Polling consistently shows that over 70 percent of Americans support medical marijuana legalization, and a strong majority supports broader legalization. With midterm elections approaching, the president's comments position him on the popular side of a formerly divisive issue.

The move also creates an interesting dynamic with the counter-legalization movement. In states like Massachusetts, Arizona, and Oklahoma, ballot initiatives seeking to repeal or restrict cannabis programs are gaining traction. Trump's endorsement of medical cannabis may complicate these efforts, particularly in states where conservative voters take cues from the president.

What Comes Next

The June 29 DEA hearing represents the next major milestone. If the hearing results in broader Schedule III classification for all cannabis, it would trigger a cascade of changes across banking, taxation, research, and interstate commerce.

For now, the industry is parsing Trump's words alongside the DOJ's order, looking for signals about the administration's long-term intentions. The president's characterization of medical cannabis as the "best alternative" suggests a level of personal conviction that could influence policy decisions well beyond the current rescheduling process.

Cannabis advocates who have spent decades working toward this moment are allowing themselves cautious celebration. The language coming from the White House has never been this friendly, and the policy changes are the most consequential since cannabis prohibition began in 1937.

Whether Trump's endorsement translates into lasting structural reform depends on what happens in June — and whether the political will exists to address the broader contradictions in American cannabis policy.

For patients ready to act on a medical cannabis recommendation, you can find a dispensary near you on Budpedia and filter by medical license to see which retailers in your state are credentialed to serve registered patients.